Blog
Could Opioids Treat Depression? This Biotech Plans to Find Out
Every year, about 17.3 million adults in the U.S. will experience at least one major depressive episode. Approximately 1 in 3 will fail to see improvement in their symptoms after treatment involving
3 High-Yield Dividend Stocks to Consider Buying Right Now
The coronavirus pandemic has changed the world in a truly short span of time. It is difficult to say when a treatment or vaccine for the coronavirus will become available. Though approaches to
IQIYI Inc (IQ) Q1 2020 Earnings Call Transcript
Image source: The Motley Fool.
IQIYI Inc (NASDAQ: IQ)Q1 2020 Earnings CallMay 19, 2020, 8:00 p.m. ET
Operator
Source Fool.com
23andMe Is Trying to Crack the Genetic Code Behind the Coronavirus
The coronavirus has swept across the globe in recent months, and companies in all sectors of the healthcare industry have stepped up to combat the pandemic. Many are now scrambling to develop a
3 Stocks Peter Lynch Would Love
Peter Lynch is a name that may be lost on some younger investors, but no one dominated the mutual fund game in the 1980s the way he did. His no-nonsense approach to identifying winners made the
Equity Residential Reports Uptick in Delinquencies, But Also Signs of Resiliency
The COVID-19 crisis has been particularly harsh on the financial sector, especially among real estate investment trusts (REITs). The mortgage REIT sector has been absolutely crushed, and retail/mall
48% of Workers Retire Earlier Than Planned -- and That Figure Could Rise Due to COVID-19
There's a danger in having to retire earlier than expected. When you're forced out of the workforce at a younger age than you've initially planned for, you risk falling short on retirement savings
3 Healthcare Stocks With Sustainable Competitive Advantages
For much of the past three months, Wall Street has been taken on a once-in-a-lifetime ride. Panic surrounding the spread of the coronavirus disease 2019 (COVID-19) wound up pushing the benchmark S&P
2 Growth Stocks Crushing the Market This Year
The S&P 500 has taken a beating in 2020 in the wake of the novel coronavirus pandemic, which has stalled businesses and economies around the world. But a few companies have seen a surge in demand
Is Abbott Labs Stock a Buy After Its COVID-19 Test Controversy?
Did the White House and others celebrate Abbott Labs' (NYSE: ABT) super-fast COVID-19 diagnostic test too soon? Some think so.
A study conducted by researchers at New York University found that
Warren Buffett Just Dumped Goldman Sachs -- Here's Why I'm Not Selling
Berkshire Hathaway's (NYSE: BRK.A) (NYSE: BRK.B) stake in investment banking giant Goldman Sachs (NYSE: GS) originated from a savvy investment CEO Warren Buffett made around the time of the
Why Aurora Cannabis' Big Bounce Might Not Last Very Long
It's been quite a while since anyone could point to Aurora Cannabis (NYSE: ACB) as a hot pot stock. But that's an apt description for the Canadian cannabis producer after it announced surprisingly
Collecting Unemployment Benefits Due to COVID-19? Prepare for a Hefty Tax Bill
Millions of Americans have been hit hard financially due to the coronavirus pandemic. Approximately 36.5 million U.S. adults have filed for unemployment benefits over the past two months, according
Will Arrowhead Pharmaceuticals Be a Biotech Winner?
With seven gene silencing candidates currently in clinical trials, Arrowhead Pharmaceuticals (NASDAQ: ARWR) is making rapid progress in developing solutions to some of the rarest and most
Is Sorrento Therapeutics Stock a Buy After Its Promising Coronavirus News?
You know a company has some really good news when its stock skyrockets 144% in a single day. That's exactly what Sorrento Therapeutics (NASDAQ: SRNE) shares did on Friday. And it looked like the
3 Great Stocks to Buy If You Get a Second Stimulus Check
Some Americans are still waiting on their stimulus checks from the CARES Act. But that's not stopping representatives in Washington, D.C., from pushing for another wave of economic stimulus. The
Where Will Adaptimmune Be in 5 Years?
The road to success for most companies, biotechs included, is far from straight forward. Investors want to find those diamonds in the rough whose stock will substantially outperform, not just in the
Warren Buffett's 3 Most Surprising Moves in Q1
Following the closing bell this past Friday, May 15, perhaps the most-anticipated Securities and Exchange Commission filing of the month became public. Namely, the Form 13F filing from Warren
What's Behind Axsome Therapeutics' Miracle Pipeline?
In the biotech industry, companies are able to successfully advance a drug from phase 2 to phase 3 studies and beyond about 50% of the time. But Axsome Therapeutics (NASDAQ: AXSM) is currently
Why I’m Not Bothering With a Social Security Strategy
Search the internet, and you'll see plenty of articles written by personal finance experts explaining why they plan to claim Social Security at a certain age. It's always helpful to understand
3 Stocks That Can Make You Rich
Following an 11-year bull market, the past three months have been highly unnerving for investors. Since the broad-based S&P 500 hit an all-time closing high exactly three months ago, on Feb. 19
Is Amarin Stock a Buy?
Irish biopharmaceutical company Amarin (NASDAQ: AMRN) posted record revenue of $155 million in its first-quarter earnings reported April 30, marking an 112% year-over-year increase for a net loss of
Baidu, Inc. (BIDU) Q1 2020 Earnings Call Transcript
Image source: The Motley Fool.
Baidu, Inc. (NASDAQ: BIDU)Q1 2020 Earnings CallMay 19, 2020, 9:15 p.m. ET
Operator
Source Fool.com
Moderna Plans to Raise $1.25 Billion in a Secondary Offering
Taking advantage of its monstrous 339% share price gain this year, including today's 20% gain on promising phase 1 data for its COVID-19 vaccine mRNA-1273, Moderna (NASDAQ: MRNA) plans to raise a
JPMorgan Chase Declares Fresh Common Stock Dividend; Yield is Just Under 4%
JPMorgan Chase (NYSE: JPM) has elected to maintain its current common stock dividend policy. On Monday, the company's board of directors declared that the sprawling bank's next quarterly payout


